



Gamma-hydroxybutyrate abuse: pharmacology and 
poisoning and withdrawal management
Enrico Marinelli1, Renata Beck2, Antonio Malvasi3, Alfredo Fabrizio Lo Faro4, and Simona Zaami1
1 Department of Anatomical, Histological, Forensic, and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy 
2 Department of Anaesthesia, Santa Maria Hospital, GVM Care & Research, Bari, Italy 
3 Department of Obstetrics and Gynaecology, Santa Maria Hospital, Bari, Italy 
4 Section of Legal Medicine, Department of Excellence SBSP, University “Politecnica delle Marche” of Ancona, 
Ancona, Italy
[Received in July 2019; Similarity Check in July 2019; Accepted in March 2020]
Gamma-hydroxybutyrate (GHB) is a central nervous system depressant primarily used as a recreational drug of abuse, 
but also for the treatment of narcolepsy with cataplexy in adult patients and as an adjuvant for control of alcohol withdrawal 
syndrome. The main aim of this review is to summarise updated knowledge about GHB pharmacokinetics and 
pharmacodynamics, acute poisoning, and clinical features of GHB withdrawal syndrome, its diagnosis and medical 
treatment. The most common clinical signs and symptoms of acute poisoning include sleepiness to deep coma, bradycardia, 
hypotension, and respiratory failure. Therapy is essentially supportive and based on continuous monitoring of vital signs. 
GHB withdrawal syndrome shares patterns with other withdrawal syndromes such as alcohol withdrawal and is sometimes 
difficult to distinguish, especially if toxicological tests are GHB-negative or cannot be performed. There are no official 
detoxification protocols for GHB withdrawal syndrome, but its therapy is based on benzodiazepine. When benzodiazepine 
alone is not effective, it can be combined with barbiturates or antipsychotics. Information about abuse and distribution 
of GHB and its precursors/analogues among the general population is still limited. Their prompt identification is therefore 
crucial in conventional and non-conventional biological matrices, the latter in particular, to clarify all the issues around 
this complex molecule.
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Gamma-hydroxybutyrate (GHB) is an endogenous 
precursor of gamma-aminobutyric acid (GABA) and a 
central nervous system (CNS) depressant that has become 
notorious because of its abuse as a recreational drug in the 
form of a colourless, odourless liquid or white powder, 
tablet, and capsule under a number of street names 
(“Georgia Home Boy”, “Juice”, “Liquid Ecstasy”, “Mils”, 
“G”, “Liquid X”, “Liquid G”, and “Fantasy”) (1, 2). Under 
the commercial name Xyrem® it has been approved for the 
treatment of narcolepsy with cataplexy in adult patients in 
the US and Europe and under the commercial name 
Alcover® for the adjuvant treatment of alcohol dependence 
and withdrawal in Europe (3, 4).
GHB can easily be obtained from and even replaced by 
abusers with its synthetic precursors and analogues gamma-
butyrolactone (GBL) and 1,4-butanediol (1,4-BD), which 
are sold as solvents for industrial use and are therefore 
available for purchase (Figure 1) (5–7).
As the issue of GHB abuse has been widespread and is 
still raising a number of questions, we wanted to put together 
all the updated information we know about its 
pharmacokinetics and pharmacodynamics, acute poisoning, 
and the clinical features of GHB withdrawal syndrome, its 
diagnosis, and medical treatment. We also wanted to provide 
some background information about GHB history, trends, 
and context of (ab)use.
LITERATURE SEARCH
Our Pubmed and Scopus search included a wide date 
span from 1970 to 2019 with the following key words: 
“gamma-hydroxybutyrate”, “gamma-butyrolactone”, 
“1,4-butanediol”, “GHB pharmacokinetics”, and “GHB 
pharmacodynamics” alone or in combination with “GHB 
acute toxicity” and “GHB withdrawal syndrome”. Besides 
these two databases, we also ran an Internet search that 
returned several books, non-indexed sources, and 
institutional websites. Of the 1,150 sources found, we 
excluded 305 duplicates. We then checked the remaining 
845 to see if they matched our interests. Only 55 papers 
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were considered appropriate for this review. All were 
written in English and were original research articles or 
reviews.
GHB TRENDS, CONTEXT OF USE, AND 
FORENSIC TOXICOLOGY ISSUES
Information about the trends of GHB use (including 
GHB analogous/precursors) among general population is 
limited, unlike with many other drugs (8). A recent report 
by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (9) says that the consumption of 
GHB and it analogues/precursors is generally low in 
Europe, save for particular contexts such as gay nightclubs 
(10–13). In this context of chemsex, GHB is frequently 
combined with synthetic cathinones (14) and other new 
psychoactive substances. It is a risky practice that has been 
reported for acute poisoning and even fatalities (15).
According to the Independent Drug Monitoring Unit 
(IDMU) report in 2003 (16), GHB use peaked between 
1994 and 2002, and before 1990 very few people used it. 
GHB and its analogues/precursors are usually taken by 
young adults aged between 19 and 22, who had tried many 
other substances before (16, 17). Another US study (18) 
reports a steady decline in GHB use from 2000 (the year in 
which GHB was declared illegal in the US) to 2008.
Even so, the issue of high mortality risk remains. GHB 
and its precursors/analogues are commonly detected in ante 
and post-mortem conventional and non-conventional 
biological matrices (mainly vitreous humour, hair, and nails) 
(19) by ultra-high performance liquid chromatography 
tandem mass spectrometry (UHPLC-MS/MS) and gas 
chromatography tandem mass spectrometry (GC-MS/MS) 
(20, 21). Cases of GHB adulteration have most often been 
reported in connection with chemsex (22, 23). Taking into 
account that this compound is both endogenous and 
exogenous, cut-offs play a key role in distinguishing 
between the two. In samples taken from living subjects 
these are 5 mg/L for blood and 10 mg/L for urine, whereas 
in post-mortem specimens they are 30 mg/L and 50 mg/L 
for peripheral and central blood, respectively and 10 mg/L 
for urine (24, 25).
GHB HISTORY
The first case of GHB synthesis dates back to 1874 and 
was reported by A. Zaytseff (26). Pioneering research on 
the effects of GHB in humans was led by Dr Laborit in the 
early sixties (25). In 1964, GHB was used as an anaesthetic, 
but has not taken root because of the considerable number 
of adverse effects. From the 1970s to 1980s, many cases of 
GHB abuse were reported among body builders for its 
alleged potential to increase growth hormones (27). 
Throughout the 1980s and 1990s, it gained notoriety as a 
stimulant of sexual performance, especially among regular 
nightclub goers (1, 2). Since the 1990s, GHB has gained 
more attention because of numerous cases of acute 
poisoning. In 2000, the US Drug Enforcement Agency 
(DEA) included GHB in Schedule I of drugs due to its 
potential for abuse and for physical and psychological 
dependence. In 2003, it was listed as a Class C drug in the 
UK Misuse of Drugs Act.
As a drug of abuse, GHB is under control in all the EU 
member states. However, it has also found application in 
the treatment of narcolepsy and less frequently as an 
adjuvant in the control of alcohol withdrawal syndromes 
and alcohol dependence (2, 28, 29).
GHB PHARMACODYNAMICS
GHB is both GABA precursor and metabolite and a 
neuromodulator in the GABA system. Neurons that release 
GABA are mostly localised in the hippocampus, cortex, 
and amygdala, which is where G protein-coupled receptors 
(GPCRs) (30, 31) are also located in pre and post-synaptic 
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Figure 1 Chemical structures of GHB, GBL, and 1,4-BD
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Excretion
According to many animal studies, GHB excretion is 
non-linear. The same was observed in the eight volunteers 
after oral administration of a therapeutic GHB dose (29).
In the study with 12 healthy volunteers referred to above 
(30), urinary GHB concentration dropped below the 
endogenous cut-off of 5 mg/L in eleven of them six hours 
after administration, which suggests that only a small 
percentage (from 0.6 to 2.5%) is excreted in urine (35–37).
ACUTE POISONING WITH GHB
Clinical presentation
Acute GHB poisoning can pose a medical challenge 
because it starts with unspecific symptoms shared by other 
acute poisonings with depressants.
In a retrospective study of 88 patients (61 men and 27 
women, mean age 28 years) treated for acute GHB 
poisoning 59 ingested other substances as well, mainly 
alcohol (34 patients) and amphetamines (25 patients). In 
53 patients the Glasgow Coma Scale (GCS) score was 
below 9. Of them, 25 patients had the GCS score 3 and 28 
from 4 to 8 (39). The most common clinical signs were 
bradycardia (present in almost all patients with the GCS 
score under 8), frequently accompanied by hypotension, 
then hypothermia (21 patients), and acute respiratory 
acidosis. Tachycardia and hypertension were early clinical 
manifestations, usually occurring 15–30 min after ingestion 
(39).Almost all patients regained consciousness 
spontaneously within five hours of GHB ingestion.
cells. After endogenous release, GHB binds to these 
receptors. However, to bind to the GABA-B receptor and 
exert its adverse effects, it must reach much higher levels 
obtained only with exogenous administration, because GHB 
is in fact a weak GABA-B agonist.
Its high affinity for receptors other than GABA-B has 
explained some of its pharmacological effects such as GHB-
induced cataplexy in certain animal studies because of the 
involvement of N-methyl-D-aspartate (NMDA) receptors 
(32, 33).
GHB can also affect other neurotransmitter systems 
such as serotonergic and more notably dopaminergic. Some 
studies show that, after initial inhibition of dopamine 




GHB shows good absorption after oral administration. 
In a study with eight male healthy volunteers receiving 12.5, 
25, and 50 mg/kg of GHB (29) its time to reach maximum 
blood concentration (Tmax) ranged between 20 and 60 min 
and correlated with the dose (25, 30, and 45 min in average, 
respectively). On the other hand, the maximum blood 
concentration achieved (Cmax) did not vary considering the 
received doses (23, 23, and 20 µg/mL respectively), which 
suggests that GHB absorption is limited.
In another study with 12 healthy volunteers (six men 
and six women) (30) who received a single 25 mg/kg dose 
of GHB mean urine Tmax was 1 h and Cmax 67.6 µg/mL, 
whereas blood Tmax was 24.6 min and Cmax 48.0 mg/L.
Distribution
The mean volume of distribution varies from 192 to 
741 mL/kg in healthy volunteers and from 225.9 to 307 mL/
kg in patients with narcolepsy and liver failure (37–39). No 
significant variations have been observed between the sexes 
or associated with concomitant food intake. GHB can cross 
the placental barrier. Its capacity of binding plasma proteins 
is reduced.
Metabolism
Over 90 % of the administered dose of GHB undergoes 
hepatic metabolism by several enzymatic pathways and is 
closely related to GABA metabolism. The main route is 
oxidation by GHB dehydrogenase to produce succinic 
semialdehyde, which is further oxidised into succinic acid. 
Further metabolism via the Krebs cycle transforms it into 
carbon dioxide and water (Figure 2) (37–39).
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Figure 2 Synthesis of GABA from glutamate and metabolism into 
succinic semialdehyde or GHB (adapted from reference 37)
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There where GHB is taken with other substances, 
clinical presentation and management require more 
attention, because these other substances can “mask” some 
of the symptoms (2, 40).
Considering that GHB is a depressant acting on the 
central nervous system, the effects of acute poisoning can 
range from sleepiness to deep coma. They usually occur 
15–50 minutes after ingestion and are short lived, which 
mainly depends on the dose. In most cases, neurological 
effects resolve within six hours. As a rule, management is 
supportive (29).
Table 1 shows neurological symptoms of acute GHB 
poisoning.
The most common respiratory manifestation is 
bradypnoea, which is often accompanied by type 2 
respiratory failure.
The most common gastrointestinal symptoms are 
vomiting (present in 20–55 % of cases, as reports vary in 
this respect), abdominal pain, and sialorrhoea (40–43).
Determination and treatment
To distinguish between exogenous and endogenous 
GHB, a threshold commonly used for samples taken from 
living patients is 10 mg/L in urine, and 5 mg/mL in blood. 
GHB is not stable in either and its concentration increases 
with time after sampling. In post-mortem blood, endogenous 
GHB concentrations can be much higher (see above) 
(44–47).
There are many methods for GHB detection in urine 
and blood. The most common is gas chromatography (GC) 
coupled with mass spectrometry (MS) or flame ionisation 
detection (FID). In addition, a number of liquid 
chromatography tandem mass spectrometric (LC-MS/MS) 
methods have recently been developed, which detect GHB 
after solid phase extraction (SPE) (48–50).
Therapy is essentially supportive and based on 
continuous monitoring of vital signs. Particular attention is 
paid to the cardiovascular and respiratory symptoms 
described earlier in the text.
Intubation is indicated in unconscious patients who are 
vomiting to prevent aspiration and choking.
Many substances such as (naloxone, flumazemil, or 
GABAB antagonists have been tried as potential antidotes, 




The clinical presentation of GHB withdrawal syndrome 
is similar to other withdrawal syndromes, alcohol and 
benzodiazepine in particular. This is the reason why it can 
sometimes be very difficult to distinguish between them, 
especially if GHB tests are negative or could not be run (4, 
60–63).
Considering the limited time of GHB action and its 
rapid elimination, signs and symptoms of GHB withdrawal 
syndrome soon become apparent, usually within 1–6 h after 
the last administration.
The withdrawal symptoms, however, can last for quite 
a while, 14 days or even more. They include anxiety, 
different degrees of depression, cognitive deficits, persistent 
insomnia (56, 57), tremor, and tachycardia, which is often 
accompanied by hypertension. Other common clinical 
manifestations include confusion, disorientation, and 
paranoia. They usually last between three and 21 days (58).
Most people with dependency have been taking GHB 
and/or its analogues/precursors for less than two years, and 
the first manifestations appear as soon as 8–13 weeks into 
the use.
In a retrospective study (59) of eight patients with 
chronic GHB use, the first clinical manifestations of 
withdrawal appeared as quickly as 1–6 h after the 
administration of the last dose, and symptoms lasted 
between 5 and 15 days. Within 24 h from the last dose 
manifestations included severe anxiety and insomnia, 
moderate nausea, and vomiting. In the following five days, 
anxiety and insomnia continued, accompanied by delirium, 
confusion, and visual hallucinations. Seven to 15 days after 
the last dose, moderate anxiety, confusion, insomnia, and 
visual hallucinations persisted only episodically. Delirium 
was more frequent in patients who had been taking GHB 
every 30 min to 8 h than in those taking it every 1–24 h.
Management and therapy
Case studies presented in medical literature provide 
general guidelines based on experience and common 
symptoms with other withdrawal syndromes, but there are 
no formal detoxification protocols for GHB or its analogues. 
Withdrawal therapy is based on benzodiazepine and when 
benzodiazepine alone is not effective against severe 
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Table 1 Neurological symptoms of acute GHB poisoning
Very common symptoms Common symptoms Less common symptoms
Ataxia, disorientation, dizziness, 
confusion, hallucinations, 
somnolence, slurred speech, myosis
Dysarthria, confusion, headache, 
incoordination, euphoria, amnesia, 
hypotonia, hyporeflexia, tremor, 
myoclonus, horizontal and vertical 
gaze nystagmus
Bruxism, vertigo, disinhibition, 
increased sexual arousal, delusions, 
extrapyramidal side effects, dystonias, 
athetosis, mydriasis
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symptoms, it can be combined with barbiturates, baclofen, 
and antipsychotics (4, 60–63).
McDonough et al. (63) have come up with an algorithm 
(Figure 3) which takes into account the number of GHB/
analogue consumption in terms of amount and frequency 
per day. If a patient has been taking three or more doses or 
more than 30 g of GHB a day, the therapy should include 
diazepam (80–150 mg) for the first seven days. If the patient 
is in delirium, diazepam doses should be upped, and if the 
symptoms persists over 24 hours, adjuvant pentobarbital is 
recommended. If a patient has been taking less than three 
doses or 30 g of GHB/analogue a day, administration of 
lower doses of diazepam (20–40 mg) should suffice (63).
NEW FRONTIERS IN GHB
GHB is currently under legal control in a number of 
countries. Because of that, pushers and users have switched 
to two GHB precursors, GBL and 1,4-BD, which can still 
be legally purchased. GBL has become a growing public 
health issue because it is relatively cheap and easy to obtain 
due to many industrial uses (7). For this reason, the two 
prodrugs were also included in the UK Misuse of Drugs 
Act in 2009. Italy has also included GBL in its Table IV of 
the Narcotics Act (Presidential Decree 309/90) but not 1,4-
BD.
GBL for recreational purposes is usually taken in its 
liquid form orally. One millilitre of pure GBL contains about 
1.6 g of GHB. As the purity of GBL diminishes so does the 
amount of GHB. GBL tastes like stale water and smells like 
burnt plastic, whereas GHB is odourless and slightly salty. 
Both are colourless (64).
After ingestion and absorption in the gastrointestinal 
tract GBL rapidly metabolises into GHB by lactonase 
enzymes in the blood. GBL-naïve users could have a 
delayed or weakened effect of GHB, whereas people who 
have already taken this drug will experience the normal full 
effects due to increased production of lactonase enzymes 
(65, 66).
GBL is more lipophilic, more quickly absorbed by the 
gastrointestinal tract, and more bioavailable than its active 
metabolite GHB. These pharmacokinetic properties make 
GBL more potent and faster than GHB, but its effects last 
less time (65–67).
CONCLUSION
Information about GHB/precursor/analogue use and 
their distribution among the general population is limited. 
What we know is that it is used alone or in combination 
with other substances such as sexual and cognitive 
enhancers, new psychoactive substances, and alcohol (22, 
68, 69). Their prompt identification is therefore crucial in 
conventional and non-conventional biological matrices, the 
latter in particular (70, 71) to clarify all the issues around 
this complex molecule.
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Zloporaba gama-hidroksibutirata – farmakologija, trovanje i liječenje ovisnosti
Gama-hidroksibutirat (GHB) depresiv je središnjega živčanog sustava koji se ponajviše zlorabi kao rekreativna droga, 
ali se primjenjuje i za liječenje narkolepsije s katapleksijom u odraslih bolesnika te kao pomoćni lijek u kontroli sindroma 
odvikavanja od alkohola. Ljudi i endogeno proizvode GHB, budući da je on prekursor gama-aminomaslačne kiseline 
(GABA), jednoga od glavnih neurotransmitera s inhibicijskim učinkom na živčani sustav. GHB ima ulogu neuromodulatora 
u GABA sustavu i uglavnom djeluje preko GABAB receptora. Za zloporabu se čestu kupuju GBH prekursori/analozi 
gama-butirolakton (GBL) i 1,4-butanediol (1,4-BD) u obliku otapala namijenjenih legalnoj industrijskoj uporabi. Oni, 
međutim, nisu endogeni. Glavni je cilj ovoga preglednog rada bio sažeti najnovije spoznaje o farmakokinetici i 
farmakodinamici GHB-a, akutnom trovanju i o kliničkim značajkama sindroma odvikavanja od GHB-a, njegovoj dijagnozi 
i liječenju. Akutno je trovanje GHB-om donekle i dijagnostički izazov jer su znakovi i simptomi uobičajeni i za depresive 
središnjega živčanog sustava. Najčešći su klinički znakovi akutnoga trovanja pospanost (sve do duboke kome), bradikardija 
i hipotenzija te respiratorno zatajenje. Liječenje je u osnovi potporno, uz stalno praćenje vitalnih znakova. Sindrom 
odvikavanja od GHB-a dijeli značajke s drugim sindromima odvikavanja (npr. od alkohola ili benzodiazepina). Ponekad 
ih je vrlo teško razlikovati, ponajviše kada su testovi na GHB negativni ili nije moguće napraviti toksikološku analizu. 
Ne postoje službeni protokoli za detoksikaciju od GHB-a ili njegovih prekursora/analoga. Liječenje se temelji na primjeni 
benzodiazepina te, ovisno o težini simptoma, sekundarno barbituratima ili antipsihoticima.
KLJUČNE RIJEČI: akutna toksičnost; GABA; gama-aminomaslačna kiselina; gama-butirolakton; 1,4-butanediol; GHB; 
farmakodinamika; farmakokinetika; sindrom odvikavanja
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